Beta
Trial Radar KI
enums.trial_summary.trial_summary_welcome
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

Exercise in Metastatic Breast Cancer: EMBody

Offene Rekrutierung
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT05468034 ist eine interventionsstudie zur Untersuchung von Brustkrebs, Indolent Metastatic Breast Cancer und hat den Status offene rekrutierung. Die Studie startete am 26. April 2023 und soll 100 Teilnehmer aufnehmen. Durchgeführt von Indiana University ist der Abschluss für 1. Dezember 2027 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 1. Mai 2025 aktualisiert.
Kurzbeschreibung
The purpose of this study is to study exercise in a novel population with indolent MBC (no progression on current therapy in prior 12 months and not receiving cytotoxic chemotherapy). The study team hypothesizes that delivering virtual, supervised, progressive intensity aerobic and resistance training exercise for 16 weeks in this population will significantly improve 1) cardiorespiratory fitness, functional status, and sarcopenia (low muscle mass), all established predictors of survival, and 2) patient- reported outcomes.
Ausführliche Beschreibung

This is a randomized, two arm, single-center study designed to compare the effect of exercise versus usual care control on the clinical parameter of cardiorespiratory fitness, in patients with metastatic breast cancer with indolent disease biology over a 16-week period. This study will be enrolling up to 100 participants. Participants will be randomized 1:1 in blocks of 4 to the exercise intervention or usual care, stratified by frailty yes/no defined by baseline SPPB score ≤ 8 or > 8.

Primary Objective To compare the effect of a 16-week multimodality, virtually delivered exercise intervention on cardiorespiratory fitness measured by a modified Bruce ramp protocol treadmill test to usual care, in patients with indolent metastatic breast cancer.

Secondary Objectives

  1. To compare the effect of exercise versus usual care on objective physical function measured by the short physical performance battery (SBBP)
  2. To compare the effect of exercise versus usual care on subjective physical functioning measured by PROMIS-29 questionnaire
  3. To compare the effect of exercise versus usual care on body composition, measured by visceral adiposity, lean muscle mass, and muscle density on CT scans obtained as standard of care using SliceOmatic software
  4. To compare the effect of exercise versus usual care on objective physical activity measured by accelerometer wear
  5. To compare the effect of exercise versus usual care on patient reported outcomes, including fatigue (BFI) and health related quality of life (PROMIS-29)
  6. To determine the fidelity of the exercise intervention, measured by changes in measures of constructs of habit and intention administered by questionnaire
  7. To describe patient uptake and adherence with the intervention, measured by proportion of approached patients who consent to the study, and proportion of assigned training sessions attended by patients randomized to the exercise arm.
Offizieller Titel

Exercise in Metastatic Breast Cancer: EMBody

Erkrankungen
BrustkrebsIndolent Metastatic Breast Cancer
Publikationen
Wissenschaftliche Artikel und Forschungspapiere zu dieser klinischen Studie:
Weitere Studien-IDs
  • CTO-IUSCCC-0781
NCT-Nummer
NCT05468034
Studienbeginn (tatsächlich)
2023-04-26
Zuletzt aktualisiert
2025-05-01
Studienende (vorauss.)
2027-12
Geplante Rekrutierung
100
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Offene Rekrutierung
Stichwörter
breast cancer
indolent metastatic breast cancer
exercise
Primäres Ziel
Supportivtherapie
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellExercise Intervention
Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
Bewegungsintervention
Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
Keine InterventionUsual Care
Participants randomized to usual care (UC) will receive care per their treatment team. UC participants are encouraged to exercise but will not be provided components of the intervention. Participants in the UC arm will be given usual care handouts at baseline from the American College of Sports Medicine.
Nicht zutreffend
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Change in cardiorespiratory fitness
Measured by minutes on the treadmill
baseline, 16 weeks
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
physical performance battery
total score on short physical performance battery
baseline, 8, and 16 weeks
Mean quality of life, as measured by the Patient-Reported Outcomes Measurement Information System-29
Likert-scaled questionnaire, with response scores ranging from 1 to 5. Scores alternate from 1 or 5 being the lowest value.
baseline, 8, and 16 weeks
muscle mass
measured by mg/kg2 on HU on PET/CT scans
baseline, and 16 weeks
muscle density
measured by mg/kg2 on HU on CT scans
baseline, and 16 weeks
adipose mass
measured by mg/kg2 on HU on CT scans
baseline, and 16 weeks
Change in physical activity minutes
measured by accelerometer data
baseline to post 16-week intervention
Change in steps per day
measured by accelerometer data
baseline to post 16-week intervention
Mean fatigue score as measured by the basic fatigue inventory (BFI)
Likert-scaled questionnaire, with response scores ranging from 0 to 10, with 10 being the worse response.
baseline, and16-weeks
Change intention and habits, as measured by the Behavioral Theory Scales
Likert-scaled questionnaire, measured with a 5-point Likert scale with response options ranging from "strongly disagree" to "strongly agree." Total scores are summed in the range of 40 to 200, with a higher score indicating stronger motivation that could predict exercise behavior.
baseline, and 16-weeks
Uptake of the study
the proportion of total patients approached, screened, and ultimately completing the baseline assessments
date open to accrual until closed to accrual, up to 2 years
Adherence with the intervention defined
the proportion of scheduled sessions attended by participants randomized to the exercise intervention arm
baseline to post 16-week intervention
change in patient-reported functional limitations, as measured by a functional limitations scale
mean score of 5 question scale, where participants responses are either scored 0 or 1, with "some difficulty" a 1 and "no difficulty" as a 0.
baseline, and16-weeks
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle

  1. Age ≥ 18 years

  2. Diagnosis of metastatic breast cancer

  3. No progression of disease in the 12 months prior to screening per the treating investigator

    1. If participant has changed treatments in the prior 12 months for reasons other than progressive disease, they remain eligible
    2. Participants on no treatment or "no evidence of disease" but still with a diagnosis of metastatic breast cancer are eligible

  4. ECOG performance status of 0-2

  5. Ability to walk on a treadmill without assistive device.

  6. Informed consent and authorization of the release of health information must be obtained according to institutional guidelines

  7. Currently not meeting physical activity guidelines (defined as less than 150 minutes of moderate to vigorous exercise per week measured by the RPAQ questionnaire administered during screening)

  8. Participants should have a cellular device compatible with iOS 15 or Android operating system 7.

  1. Receiving cytotoxic chemotherapy at any point in the prior 12 months.

    1. Participants receiving endocrine therapy are eligible.
    2. Participants receiving targeted therapy or antibody therapy are eligible (examples including trastuzumab, pertuzumab, TDM-1, trastuzumab deruxtecan, sacituzumab govetecan, immunotherapy, CDK4/6 inhibitors, olaparib, alpelisib, etc.)

  2. Any condition precluding supervised exercise participation. A letter from a physician supporting participation can supercede this eligibility criteria.

    • NYHA class III or IV congestive heart failure
    • Uncontrolled angina
    • Myocardial infarction in the prior 12 months
    • Orthopedic surgery in the previous 3 months or plans for orthopedic surgery during the study period
    • Chronic uncontrolled pulmonary conditions such as uncontrolled asthma (symptoms > 2 days/week) or dyspnea requiring oxygen
    • Symptomatic peripheral vascular disease
    • Or any other comorbidity that would interfere with the ability to complete and comply with the protocol in the opinion of the investigator, including psychological illness
    • History of fragility fracture

  3. Active, untreated brain metastases

Indiana University logoIndiana University288 aktive klinische Studien zum Erkunden
Verantwortliche Partei
Tarah J Ballinger, MD, Hauptprüfer, Assistant Professor of Clinical Medicine, Indiana University
Zentrale Studienkontakte
Kontakt: Malori Pojar, (317) 274-0899, [email protected]
Kontakt: Tarah Ballinger, MD, [email protected]
6 Studienstandorte in 1 Ländern

Connecticut

Yale Cancer Center, New Haven, Connecticut, 06510, United States
Brenda Cartmel, PhD, Kontakt, 203-737-5091, [email protected]
Tara Sanft, MD, Hauptprüfer
Offene Rekrutierung

Indiana

IU Health West, Avon, Indiana, 46123, United States
Malori Pojar, Kontakt, (317) 274-0899, [email protected]
Tarah Ballinger, MD, Hauptprüfer
Offene Rekrutierung
IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, 46032, United States
Malori Pojar, Kontakt, (317) 274-0899, [email protected]
Tarah Ballinger, MD, Hauptprüfer
Offene Rekrutierung
Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States
Malori Pojar, Kontakt, (317) 274-0899, [email protected]
Tarah Ballinger, MD, Hauptprüfer
Offene Rekrutierung
Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, 46202, United States
Malori Pojar, Kontakt, (317) 274-0899, [email protected]
Tarah Ballinger, MD, Hauptprüfer
Offene Rekrutierung

Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States
Anna Tanasijevic, Kontakt, 617.632.5584, [email protected]
Jennifer Ligibel, MD, Hauptprüfer
Offene Rekrutierung